Abbott received approval from the FDA for Simcor, the first fixed-dose combination of cholesterol therapies, Niaspan (Abbott’s niacin extended-release) and simvastatin. Simcor is approved for use along with diet to lower levels of elevated total cholesterol, LDL “bad” cholesterol and triglycerides, and to raise HDL “good” cholesterol in patients with complex lipid disease when treatment with simvastatin or Niaspan monotherapies are not adequate.     “Managi...